ZIMLAB Zim Laboratories Q1 FY26 results (Apr–Jun 2025) and concall
Zim Laboratories reported a challenging Q1 FY26 with a 12.3% YoY decline in operating income to INR718 million and a net loss of INR19 million. This was primarily due to softer order inflows in the innovation-led segment, geopolitical events in the Middle East, and the impact of an EU-GMP inspection revealing critical observations related to documentation. Despite these headwinds, the Indian business showed strong growth, and income from licensing increased significantly, with a robust product pipeline continuing to advance.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 |
|---|---|---|---|---|
| Revenue | 90 | 95 | 109 | 71 |
| EBITDA | 8 | 12 | 15 | 4 |
| Net profit | 1 | 4 | 5 | -2 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
